Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Turkey / NCT07238426
Enrolling by invitation Observational

ATTRACT-52: Primary Care Cardiac Amyloidosis Screening in Ordu, Turkey

NCT07238426 · tracked via the Priya Life Science Turkey tracker
Sponsor
Kotyora Family Medicine Health Management and Education Association
Phase
Observational
Started
2025-12-01
Last updated
2026-02-25

Condition(s) studied

Cardiac AmyloidosisTransthyretin Amyloidosis

Study summary

Cardiac amyloidosis is a progressive infiltrative cardiomyopathy, most commonly related to transthyretin (ATTR) misfolding. Although considered rare, emerging data suggest higher prevalence in specific regions, including the Black Sea area of Turkey. Early recognition improves outcomes. ATTRACT-52 is a prospective, observational, non-interventional screening study in primary care (family medicine centers) across Ordu province. Adults ≥65 years with cardiac or musculoskeletal "red flags" will be screened; those meeting high-suspicion criteria will undergo NT-proBNP/BNP testing at the primary care level to aid risk stratification prior to referral for confirmatory diagnostics.

Eligibility

Sex
ALL
Min age
65 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age ≥65 years * Registered patient in participating Family Medicine Centers (Ordu province) * Cardiac history including at least one of: heart failure (I50), aortic stenosis (I35.0), cardiomyopathy (I42), atrioventricular block (I44), or atrial fibrillation (I48) * Echocardiographic interventricular septal thickness ≥12 mm with preserved LVEF (≥50%), when available * Ability to provide verbal or written consent Exclusion Criteria: * Known systemic AL amyloidosis * Severe renal impairment (eGFR \<30 mL/min/1.73m²) * Inability to provide consent * Concurrent participation in an interventional trial

Primary outcome measure(s)

  • Proportion of high-suspicion participants with elevated NT-proBNP (>600 pg/mL) — Baseline (Day 0)
    Percentage of high-suspicion cases exceeding the predefined NT-proBNP threshold at baseline.

Trial sites (1)

FacilityCityRegionStatus
Ordu University Faculty of Medicine, Department of Cardiology Ordu Ordu

More Kotyora Family Medicine Health Management and Education Association trials in Turkey

SNAP AF-52: Dose Appropriateness and Adherence to Oral Anticoagulation in Adults ≥65 With Atrial Fibrillation in Primary Care (Ordu, Türkiye) Enrolling by invitation
PRO-AF 52: Monthly Primary-Care 12-Lead ECG Screening for Incident Atrial Fibrillation in Adults Aged ≥65 Years Enrolling by invitation
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07238426 on ClinicalTrials.gov ↗ ← All trials in Turkey